chrisvoncsefalvay/vaers-outcomes huggingface dataset:
Severe body aches; Started in her left shoulder; Head hurts bad; Low-grade fever; This spontaneous case was reported by a consumer and describes the occurrence of MYALGIA (Severe body aches), ARTHRALGIA (started in her left shoulder), HEADACHE (head hurts bad) and PYREXIA (low-grade fever) in a 62-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 031B21A) for COVID-19 vaccination.     No Medical History information was reported.    On an unknown date, the patient received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On an unknown date, the patient experienced MYALGIA (Severe body aches), ARTHRALGIA (started in her left shoulder), HEADACHE (head hurts bad) and PYREXIA (low-grade fever). At the time of the report, MYALGIA (Severe body aches), ARTHRALGIA (started in her left shoulder), HEADACHE (head hurts bad) and PYREXIA (low-grade fever) outcome was unknown. Not Provided      The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       No concomitant medications provided.  On an unknown date, the patient stated the body aches were so bad she could not get out of bed.  No treatment information provided.
ED to Hosp-Admission  Discharged  9/19/2021 - 9/23/2021 (4 days)  Last attending ? Treatment team Acute respiratory failure with hypoxia Assessment  Patient is a 75 y.o. female who presents with with past medical history of COPD, presented with generalized weakness, and shortness of breath x2 days.   Plan  1. Acute hypoxic respiratory failure: Presented with generalized weakness, cough and shortness of breath, SPO2 dropped to 77% on room air, likely due to COPD exacerbation, in light of SARS-CoV-2 pneumonia.  Supplemental oxygen by nasal cannula, keep SPO2 greater than 90%, start IV dexamethasone, and remdesivir.  send and monitor inflammatory markers.   2. COPD with acute exacerbation: Patient use 2 L of oxygen at night, CT chest showed right sided pleural thickening, mild bilateral bronchiectatic changes, with minimal patchy airspace disease. Continue treatment as #1, continue scheduled nebs, resume Breo,   3. SARS-CoV-2 pneumonia: Patient received Pfizer COVID-19 vaccine  on 3/21, nasopharyngeal swab positive for SARS-CoV-2, with mild patchy airspace disease. Continue treatment as #1, maintain Covid isolation,   4. Hyponatremia and hypokalemia: Due to decreased p.o. intake, encourage oral hydration, replace potassium    5. Essential hypertension: Resume hydrochlorothiazide   6. GERD: Resume Protonix   7. Generalized anxiety disorder: On sertraline, will continue   DVT PPX: low molecular weight heparin Dispo: 3 S., anticipate > 2 midnight inpatient stay DNR (Do Not Resuscitate)     CC: Shortness of breath and generalized weakness. HPI  Patient is a 75 y.o. female who presents with with past medical history of COPD on 2 L home oxygen at night, presented to the ED with generalized weakness, cough, shortness of breath x3 days.  Patient states that her symptoms started last Thursday when she started experiencing body aches, generalized weakness and poor appetite.  Since yesterday she has been feeling more out of breath and experienced fever.  Patient reports that her cough is dry and about the same.  Reports nausea and one episode of diarrhea this morning.
I have swelling under my left arm; Very large bump, a quarter size of a baseball; Dose number: 3; This is a spontaneous report received from a contactable reporter(s) (Consumer or other non HCP). The reporter is the patient.  A 49 year-old male patient received bnt162b2 (BNT162B2), administered in arm left, administration date 15Dec2021 17:30 (Batch/Lot number: unknown) at the age of 49 years as dose 3 (booster), single for covid-19 immunisation. Relevant medical history included: "if Covid prior vaccination: Yes" (unspecified if ongoing), notes: if Covid prior vaccination: Yes. There were no concomitant medications. Vaccination history included: Bnt162b2 (Dose Number: 1, brand=Pfizer Biontech, Batch/Lot No: Unknown. Misplaced/discarded, Location of injection: Arm Left, Vaccine Administration Time: 02:30 PM), administration date: 21Apr2021, when the patient was 48 years old, for COVID-19 immunization; Bnt162b2 (Dose Number: 2, brand=Pfizer Biontech, Batch/Lot No: Unknown. Misplaced/discarded, Location of injection: Arm Left, Vaccine Administration Time: 02:30 PM), administration date: 12May2021, when the patient was 49 years old, for Covid-19 immunization.  The following information was reported: IMMUNISATION (non-serious) with onset 15Dec2021 17:30, outcome "unknown", described as "Dose number: 3"; VACCINATION SITE SWELLING (non-serious) with onset 17Dec2021 05:45, outcome "not recovered", described as "I have swelling under my left arm"; MASS (non-serious) with onset 17Dec2021 05:45, outcome "not recovered", described as "Very large bump, a quarter size of a baseball". Therapeutic measures were not taken as a result of vaccination site swelling, mass.  Additional information: it was reported that patient did not took any other vaccine in four weeks nor any medications in two weeks. Patient was not tested covid post vaccination.  The lot number for bnt162b2 was not provided and will be requested during follow up.
With the second dose On day 2 after receiving vaccine I noticed a rash about 2 or 3 inches below of the injection site. It was very achy, slightly raised and hot to the touch. It was more severe than the 1st dose. It then spread to the whole arm, from my elbow to my shoulder. I also had moderate spots of rash on my trunk and back. Since I already had seen my dermatologist regarding the rash for the 1st dose I already had the topical cortic steroid at home and the oral antihistamine I used for the first dose and just used those. After about 10 days the symptoms cleared. I have pictures and will gladly provide them.
HIVES 24 HOURS AFTER VACCINATIONS, APPEARED ON LEFT THIGH THEN TO RIGHT THIGH THEN SPREAD TO OTHER PARTS OF BODY. TREATED WITH OVER THE COUNTER BENADRYL.
Chills, abdominal pain (not long). slight dizziness and woke up with a fever of 101.3
I contracted COVID-19 on 07/16/2022 with symptoms of cough, congestion, hoarseness, chest congestion, runny nose, and fever of 101. I was prescribed PAXLOVID on 07/19/2022. I was ill for 8 days before my symptom began to resolve. My symptoms returned and worsened on 07/28/2022. I began to improve on 08/03/2022 but my symptoms have not fully resolved yet.
experienced extreme pain in the arm (same arm where she got the vaccine); chills; throbbing arm pain; throbbing arm pain was reported as worsened; fever; This is a spontaneous report from a contactable consumer (patient). A 53-years-old female patient received first dose of BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE, formulation: Solution for injection, lot number: EN6205, patient was 53-year-old at the time of vaccination), via an unspecified route of administration, administered in Arm Left on 03Mar2021 at 01:45 PM as DOSE 1, SINGLE for covid-19 immunisation. Medical history reported as no. Concomitant medication(s) included ibuprofen (IBUPROFEN). Reported that patient particularly concerned about the arm pain she was experienced. She wanted to know if this was a normal adverse reaction with the vaccine. She also wanted to know what to do with her arm pain. She had chills the second day after the vaccine, it was that night she had the chills and fever that continued. Now she has no fever, but the pain in her arm really hurts, she can't move it. She lost 8 days of work because its really hurting. On 04Mar2021, the patient experienced fever, experienced extreme pain in the arm (same arm where she got the vaccine), chills, throbbing arm pain, throbbing arm pain was reported as worsened. Patient received treatments for events (extreme pain in the arm (same arm where she got the vaccine), throbbing arm pain, throbbing arm pain was reported as worsened) with heating pad and purchased CBD creams Over the counter to help but it's not helping. The outcome of event (chills) were unknown, and the outcomes of events (experienced extreme pain in the arm (same arm where she got the vaccine), throbbing arm pain, throbbing arm pain was reported as worsened) were not recovered and the outcomes of event (fever) was recovered on an unspecified date in 2021.   No follow-up attempts are possible. No further information is expected.
headache; fever; chills; body ache; joint pain; arm pain; The initial case was missing the following minimum criteria: Unspecified product and Unspecified AE. Upon receipt of follow-up information on 30Aug2021, this case now contains all required information to be considered valid.  This is a spontaneous report received from a contactable consumer (patient). A female patient of an unspecified age received bnt162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE), intramuscular on the Arm Left on 30Jul2021 15:26 (Batch/Lot Number: EW0196) as dose 2, single for COVID-19 immunization at a pharmacy. There were no concomitant medications. The patient has no medical history. The patient previously received the first dose of bnt162b2 (Lot number: EW0196) on 09Jul2021 12:00, Intramuscular on the Left arm for COVID-19 immunization and experienced headache and arm ache. No other prior vaccinations and relevant tests. On 30Jul2021, the patient experienced headache, fever, chills, body ache, joint pain, and arm pain all considered as important medical event by the reporter. The outcome of the events was recovered on 02Aug2021.   No follow-up attempts are possible. No further information is expected.
This spontaneous report was received from a 71-year-old female patient, who was reporting on herself. The patient's concurrent conditions included bronchiectasis with mycobacterium avium complex (MAC) lung disease. The patient did not have any drug reactions or allergies. On 13-SEP-2017, the patient was vaccinated with a single dose of PNEUMOVAX 23 injection, 0.5 ml via subcutaneous route (lot # and expiration date were not reported) for prevention of pneumococcal disease. There were no problems. Concomitant therapies included hydrochlorothiazide (HCTZ), VENTOLIN and medication reported as TORVORTATON. On 14-SEP-2017 (reported as the following evening after the injection), the patient experienced tenderness at the injection site, pain and swelling from the injection site to her elbow, achy, chills and a fever. These adverse reactions lasted on and off for the next 3 days. The patient was treating herself for the pain and swelling with over the counter medications, TYLENOL and BENADRYL at night. On 16-SEP-2017 (reported as on the 3rd day after the injection), the patient was vomiting and was very weak and shaky and during the nausea, she passed out and hit her head on the toilet. The patient did not seek medical attention and no laboratory diagnostics were performed. The outcome of nausea, weakness, shaking, vomiting, passing out and hitting her head was reported as recovering/resolving. The outcome of tenderness at the injection site, pain and swelling from the injection site to the elbow, achy, chills and a fever was reported as recovered/resolved on 16-SEP-2017. The relatedness between the adverse event and PNEUMOVAX 23 was not reported.
Stress is Mild; This case was reported by a consumer and described the occurrence of stress in a adult male patient who received Herpes zoster (Shingrix) for prophylaxis.   On an unknown date, the patient received Shingrix at an unknown dose. On an unknown date, less than 2 years after receiving Shingrix, the patient experienced stress. On an unknown date, the outcome of the stress was recovered/resolved.   It was unknown if the reporter considered the stress to be related to Shingrix.  Additional details were provided as follows: The age at vaccination was not reported. The patient reported that, after vaccination with dose of Shingrix, experienced stress. The patient reported that, the stress was mild, and it was comes and goes.
large quarter sized rash on his arm; Initial information received on 21-Nov-2019 regarding an unsolicited valid non-serious case received from a consumer/non-health care professional.  This case involves a 4 years old male patient who experienced large quarter sized rash on his arm (rash), while he received vaccine INFLUENZA QUADRIVAL A-B MULTIDOSE VACCINE PRESERVED [FLUZONE].  The patient's past medical history, medical treatment(s), vaccination(s) and family history were not provided.  Concomitant medications included MEASLES VACCINE, MUMPS VACCINE, RUBELLA VACCINE (MMR); and DIPHTHERIA VACCINE TOXOID, PERTUSSIS VACCINE ACELLULAR, TETANUS VACCINE TOXOID (DTAP).  On 21-Nov-2019, the patient received a dose of suspect INFLUENZA QUADRIVAL A-B MULTIDOSE VACCINE PRESERVED lot UJ244AA via unknown route in the left arm.  On an unknown date , the patient developed a non-serious large quarter sized rash on his arm (rash) (Unknown latency) following the administration of INFLUENZA QUADRIVAL A-B MULTIDOSE VACCINE PRESERVED.  Other relevant test was not reported.  Final diagnosis was Localised rash.   It was not reported if the patient received a corrective treatment.  The event outcome is reported as Unknown for large quarter sized rash on his arm.
Patient complained of numbness during observation after receiving the second dose of the Pfizer vaccine. EMS was called and treated the person on scene.
Breakthrough COVID-19; This spontaneous case was reported by a consumer and describes the occurrence of BREAKTHROUGH COVID-19 (Breakthrough COVID-19) in a 46-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.    Co-suspect product included non-company product UPADACITINIB (RINVOQ) for Rheumatoid arthritis.    Concurrent medical conditions included Rheumatoid arthritis.   In March 2021, the patient received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On an unknown date, the patient started UPADACITINIB (RINVOQ) (Oral) at an unspecified dose. In 2021, the patient experienced BREAKTHROUGH COVID-19 (Breakthrough COVID-19). In 2021, BREAKTHROUGH COVID-19 (Breakthrough COVID-19) had resolved.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       Concomitant products were not provided. Treatment medication were not reported. It was unknown if patient was enrolled in a covid-19 vaccine trial.  This case was identified as part of a retrospective clean-up activity where certain emails received in the Moderna mailbox were missed to be booked-in.
I haven't felt good since I got my shot. It feels like my lupus is in a flare up and it hasn't stopped. I feel sick everyday.
Upset stomach in the morning sat in his office and died suddenly of a heart attack at 11:15AM
-I got a terrible head cold 5 days after vaccine with chills and body aches. -Both my legs have broken out in what look like hives or bad razor burn.   It started around my ankles and have progressed up my legs now past my knees.  It is so so itchy and painful.  All my pores are inflamed, red, and puffed out.  -My arm muscle at the injection site got really inflamed, hard and puffed out  and sore again 7 days after vaccine.
Acute inflammation of the left hip joint; excruciating pain; increased synovial fluid in the left hip joint; unable to move, walk of bare weight on the left side; unable to move, walk of bare weight on the left side; elevated markers of inflammation in peripheral blood; highly elevated immune infiltration; This is a spontaneous report from a contactable consumer (patient). A 34-year-old female patient received bnt162b2 (BNT162B2, Solution for injection), via an unspecified route of administration, administered in Arm Left on 10Apr2021 14:15 (Lot Number: EW0150) (received at 34-years-old) as SINGLE DOSE for covid-19 immunisation. Medical history included herniated lumbar discs. The patient was not pregnant. Concomitant medication(s) included levonorgestrel (MIRENA) taken for an unspecified indication, start and stop date were not reported. The patient experienced Acute inflammation of the left hip joint, excruciating pain, unable to move, walk of bare weight on the left side, elevated markers of inflammation in peripheral blood, MRI showed increased synovial fluid in the left hip joint, analysis showed highly elevated immune infiltration present in the synovial fluid, with no presence of concurrent infection or elevated markers of systemic autoimmune disease, or secondary conditions that could lead to joint inflammation, all on 15Apr2021 05:00 AM. The patient underwent lab tests and procedures which included magnetic resonance imaging (MRI): increased synovial fluid on 15Apr2021 increased synovial fluid in the left hip joint, analysis showed highly elevated immune infiltration present in the synovial fluid; nasal swab test: negative on 16Apr2021. Therapeutic measures were taken as a result of the adverse events which included aspiration of fluid from joint, anti-inflammatories. The adverse events resulted in Doctor or other healthcare professional office/clinic visit, Emergency room/department or urgent care, Hospitalization. The patient was hospitalized for 4 days. Outcome of the events was recovering.
At exactly 5pm I was driving and starting to feel weak, I saw my left arm (not on the site of the injection) and I had raised, itchy, red rash (hives) on the front part of my elbow and forearm. I took a picture of it at exactly 5:17pm that I could stop driving.  I saw my neck and it was also itchy and red. I got home and at 5:40pm took 1 pill of loratadine 10mg, the hives vanished an hour later, the itchiness in my neck, face and arms didn't. So I took another loratadine 10mg at 10pm and applied my self an intramuscular shot of Chlorphenamine. The next morning I had no itchiness or hives on arms, though the skin around my neck and chin stills feels kind of itchy, but not like it was on saturday. I am visiting the country, I am a dentist, so I came prepared and treated myself. I just want to know if I should get or not the 2nd dose.
72 hours after TD patients seen a red, painful reaction at shot site that was worsening.
2 inch red spot on arm at site of injection. WRm to touch and tender. Some itching.
A second shot of PREVNAR 13 was administered to patient on 4/9/15 after she got one on 1/14/15. No adverse effects were reported by the patient.
Swelling and warmth to injection site of Menveo/ L Deltoid started the morning of 10/5/22
Patient noticed redness after waking up from a nap in which she had been laying on the arm that was injected with PREVNAR 13.  She came to the pharmacy 12/06/2016 and the on duty pharmacist told her to take some ibuprofen. Patient was allergic to Benadryl so it was not recommended. Patient came back on 12/7/2016 and I told to go to the doctors office.
EXTREME GASTRIC PAIN, NAUSEA, SLIGHT FEVER WITH SWEATING, MUSCLE WEAKNESS, LIGHT-HEADED. SENSATIONS LASTED FOR ABOUT 5-6 HOURS IN DURATION.
Gave the Prevnar 20 into Right thigh, about 5-10 minutes later right leg started having blotching of skin. Doctor came into and checked on pt. Had pt. stay another 10-15 min. Pt. was breathing and acting normal after vaccine and during the watching in office. Gave pt. Benadryl dosage if needed for later. Called pt. family to check on her 1 hr. Later and she was back to normal, no visible blotching.
The day after I had severe flu like symptoms-aches, chills, fevers, nausea, and swelling at injection site. After 24 hours those subside some but the aching continued for 2 more days and I cannot lift my arm above my head due to the swelling in my injection site. My underarm lymph nodes of the injection are so painfully swollen that movement hurts. Also I woke up one night ago covered in hives on my back. I got this shot on Tuesday and it is now Saturday and I am still in pain.
Mother reports child is having an "allergic reaction to the flu shot he got yesterday". States the child's face is swollen, and he has whelps "all over". She stated she is taking the child to the doctors and she will tell me the outcome on Monday, 10/24/2022.
Swollen bump that occurred immediately at the site of the injection.  The bump was gone after monitoring the patient for 15 minutes.
BlurredVision, Dizziness, Headache, Myalgia, Phlebitis, UrticariaPruritus,  Phlebitis of right arm continues  Narrative:    Other Relevant History:
Swollen painful lymph nodes on clavicle on left side, same side shot administered; Swollen painful lymph nodes on clavicle on left side, same side shot administered; dose 3; This is a spontaneous report received from a non-contactable reporter(s) (Consumer or other non-HCP). The reporter is the patient.  A 33-year-old female patient (not pregnant) received bnt162b2 (BNT162B2), administered in arm left, administration date 17Nov2021 11:15 (Batch/Lot number: unknown) at the age of 33 years as dose 3 (booster), single for covid-19 immunisation. Relevant medical history included: "Asthma" (unspecified if ongoing). Concomitant medication(s) included: ZOLOFT. Vaccination history included: Bnt162b2 (Dose Number: 2, administration time: 08:15 AM, dose vaccine location: Left arm), administration date: 30Mar2021, when the patient was 33 years old, for COVID-19 immunization; Bnt162b2 (Dose Number: 1, administration time: 11:15 AM, dose vaccine location: Left arm), administration date: 01Mar2021, when the patient was 33 years old, for COVID-19 immunization. The following information was reported: IMMUNISATION (non-serious) with onset 17Nov2021 11:15, outcome "unknown", described as "dose 3"; LYMPHADENOPATHY (non-serious), LYMPH NODE PAIN (non-serious) all with onset 18Nov2021, outcome "not recovered" and all described as "Swollen painful lymph nodes on clavicle on left side, same side shot administered". Therapeutic measures were not taken as a result of lymphadenopathy, lymph node pain.  Additional information: The patient had no known allergies. The patient did not receive any other vaccines within 4 weeks prior to the COVID vaccine. Prior to vaccination, the patient was not diagnosed with COVID-19 and since the vaccination, the patient has not been tested for COVID-19.  No follow-up attempts are possible; information about lot/batch number cannot be obtained. No further information is expected.
No additional AE; Product expired 10/7/2023 and was administered 10/16/2023.; This spontaneous report was received from a medical assistant and refers to a 16-month-old. The patient's medical history was not reported. The patient's concurrent conditions were not reported. Concomitant medications were not reported.  On 16-OCT-2023, the patient was vaccinated with an expired dose of measles, mumps, and rubella (wistar ra 27-3) virus vaccine, live (M-M-R II) subcutaneous injection (strength, and route of administration were not provided), 0.5 ml, lot # U031361, expiration date reported as 07-OCT-2023, administered for prophylaxis. The vaccine was reconstituted with a sterile diluent, lot # and expiration date were not reported. The patient had not experienced any adverse effect after vaccination.   Albumin status has been verified for measles, mumps, and rubella (wistar ra 27-3) virus vaccine, live (M-M-R II) (lot # U031361) to be recombinant human albumin (rHa).
redness, high fever, sore throat, allergic symptoms: tingling in lips, bumps in throat
On 4/28/2021 within 6 hours I began wheezing, shortness of breath, having extreme fatigue, constipation, rectal bleeding, glands were swollen in throat, body ache, dizziness, vomiting, and nausea.  After 3 days these symptoms continued. On 5/26/2021 I received the second dose, could not eat had no appetite, extreme dizziness, and severely dehydrated. Was prescribed antibiotics by healthcare professional.